Bull Case

A successful clinical or regulatory catalyst drives partner interest and non-dilutive funding, lifting revenue visibility versus small-cap biotech peers with similar binary-event dependence.

Improved financing terms reduce dilution pressure, allowing development spend to continue and preserving optionality better than peers forced into repeated equity raises.

If execution stays on schedule, milestone receipts and collaboration economics can re-rate the business model faster than peers still pre-commercial and cash constrained.

Positive data or approval momentum can expand valuation multiples from distressed levels, because current EV/sales and cash-flow metrics already imply severe skepticism versus peers.

Base Case

The company likely remains a development-stage story with intermittent funding needs, so operating losses persist and revenue inflection stays slower than more advanced peers.

Periodic capital raises or partnerships provide enough runway to advance programs, but dilution and timing risk keep economics weaker than better-capitalized biotech peers.

Absent a major catalyst, valuation remains driven by optionality rather than fundamentals, leaving the stock below peers with approved products or recurring revenue.

Execution progress can support modest sentiment improvement, yet the path to durable margin improvement remains constrained by the current negative operating profile.

Bear Case

Clinical setbacks or regulatory delays would likely compress partner appetite and financing access, worsening outcomes versus peers that maintain cleaner development momentum.

With operating margins already deeply negative, slower progress can force highly dilutive capital raises that erode per-share value faster than peer averages.

If cash burn outpaces funding, the company may need to cut programs or renegotiate terms, reducing pipeline breadth and future revenue potential.

Persistent skepticism can keep valuation depressed or lower, because the current negative cash-flow profile leaves little cushion against adverse trial or funding news.

Overall Score

PAVM’s forward path is dominated by binary development and financing outcomes, leaving upside from catalysts but a still-fragile base case relative to better-capitalized peers.